Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received market approval from China’s National Medical Products Administration (NMPA) for its R-ONE vascular intervention surgical robot. The robot was introduced by Cathbot, a joint venture between MicroPort and French firm Robocath S.A.S in China.
R-ONE, a vascular intervention navigation control system that utilizes master-slave control technology, is designed to assist cardiovascular intervention physicians in performing percutaneous coronary intervention (PCI) surgery. It enables precise localization of lesions and optimizes the delivery of balloon and stent catheters, standardizing surgical procedures, enhancing surgical accuracy, and reducing complications. Additionally, the operator can use R-ONE from behind a radiation protection console, remotely controlling the robot to significantly reduce exposure to radiation while carrying out precise surgical operations.- Flcube.com
